This trial is active, not recruiting.

Condition polycystic ovary syndrome
Treatment amh level difference between patient with pcos and multicystic ovaries.
Sponsor Izmir Katip Celebi University
Start date February 2016
End date August 2016
Trial size 60 participants
Trial identifier NCT01878955, AMH-123


AMH is a member of the transforming growth factor family. It is produced by the granulosa cells from 36th weeks of pregnancy.Ovarian granulosa cells are the only source of the antimüllerian hormone. AMH production continues until response to exogenous FSH occurs and follicles reach 4-6 mm in diameter.The number of follicles in patients with polycystic ovaries are 2-6 times higher than normal women. Serum AMH levels are 2-3 times higher in patients with PCOS. The cause of elevated serum AMH levels in patients with PCOS is unknown. There are data showing elevated serum AMH level is due to the increase in the number of follicles 2-8 mm in diameter. Although there is no precise definition; multicystic ovarian is defined by the presence of more than six follicles 4-9 mm in diameter and mixed morphologically with PCO. PCO and multicystic ovaries are distinguished by the absence of the increase in stroma / volume.The aim of this study is to investigate whether there is a difference of serum AMH levels between patients with PCO or multicystic ovaries. A primary goal is to investigate the usability of AMH as a marker besides ultrasound for discrimination of nonhyperandrogenic patients with PCO or multicystic ovaries.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Time perspective prospective
Between the ages of 18-35 patients diagnosed with PCOS according to the Roterdam criteria
amh level difference between patient with pcos and multicystic ovaries.

Primary Outcomes

Anti-Müllerian Hormone level 0.7ng/ml -3.5ng/ml.
time frame: 6 months

Eligibility Criteria

Female participants from 18 years up to 35 years old.

Inclusion Criteria: - Between the ages of 18-35 - >6 4-9 mm follicles in bilateral ovaries at ultrasonographic examination - Increased ovarian volume (>10 ml ) Exclusion Criteria: - Hormonal drug users - Late onset congenital adrenal hyperplasia,androgen secreted ovarian or adrenal tumors

Additional Information

Official title Elevation of AMH Resulted From Ovarian Structural Properties or Effects of Gonadotropines
Description It is planned to compare the values of FSH/LH, AMH, and 75 gr OGTT between 20 patients diagnosed as PCOS according to the AES-Rotterdam criteria and 20 patients with multicystic ovarian structure but do not provide the PCOS-D3 criteria. The second purpose of this study is to investigate the mechanism that leads to the elevation of AMH in patients with PCOS, and to reveal the effects of intraovarian paracrine factors,insulin resistance and FSH /LH.
Trial information was received from ClinicalTrials.gov and was last updated in February 2016.
Information provided to ClinicalTrials.gov by Izmir Katip Celebi University.